Orlin Biotech: Quadrivalent Influenza Virus Split Vaccine Initiated Phase III Clinical Trial

Orin announced that the company's quadrivalent influenza virus split vaccine has officially started phase III clinical trials based on previous clinical trials and has successfully enrolled the first subject.